Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi

European Journal of Pharmacology

Volumn 761, Issue , 2015, Pages 383-390

  Rogliani, Paola ^a,b   Calzetta, Luigino ^b   Ora, Josuel ^a   Lipsi, Roberto ^b   Segreti, Andrea ^b   Matera, Maria Gabriella ^c   Cazzola, Mario ^a,b  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Aclidinium; COPD; Glycopyrronium; Onset of action; Tiotropium

Indexed keywords

ACLIDINIUM BROMIDE; GLYCOPYRRONIUM BROMIDE; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; TROPANE DERIVATIVE;

ADULT; ARTICLE; BRONCHODILATATION; BRONCHUS; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EX VIVO STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; BRONCHOCONSTRICTION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; BRONCHI; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HUMANS; IN VITRO TECHNIQUES; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTORS; TIOTROPIUM BROMIDE; TREATMENT OUTCOME; TROPANES;

EID: 84938950539     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.04.042     Document Type: Article

References (37)

1. K. Alagha, A. Palot, T. Sofalvi, L. Pahus, M. Gouitaa, C. Tummino, S. Martinez, D. Charpin, A. Bourdin, and P. Chanez Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases Ther. Adv. Chronic Dis. 5 2014 85 98
2. L. Calzetta, C.P. Page, D. Spina, M. Cazzola, P. Rogliani, F. Facciolo, and M.G. Matera Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone J. Pharmacol. Exp. Ther. 346 2013 414 423
3. M. Cazzola, L. Calzetta, C.P. Page, P. Rogliani, F. Facciolo, A. Gavalda, and M.G. Matera Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi Eur. J. Pharmacol. 745 2014 135 143
4. M. Cazzola, L. Calzetta, P. Rogliani, D. Lauro, L. Novelli, C.P. Page, V. Kanabar, and M.G. Matera High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway Am. J. Respir. Cell Mol. Biol. 47 2012 509 516
5. M. Cazzola, L. Calzetta, A. Segreti, F. Facciolo, P. Rogliani, and M.G. Matera Translational study searching for synergy between glycopyrronium and indacaterol COPD 12 2014 175 181
6. M. Cazzola, S. Centanni, P. Santus, M. Verga, M. Mondoni, F. di Marco, and M.G. Matera The functional impact of adding salmeterol and tiotropium in patients with stable COPD Respir. Med. 98 2004 1214 1221
7. M. Cazzola, F. Di Marco, P. Santus, B. Boveri, M. Verga, M.G. Matera, and S. Centanni The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD Pulm. Pharmacol. Ther. 17 2004 35 39
8. M. Cazzola, W. MacNee, F.J. Martinez, K.F. Rabe, L.G. Franciosi, P.J. Barnes, V. Brusasco, P.S. Burge, P.M. Calverley, B.R. Celli, P.W. Jones, D.A. Mahler, B. Make, M. Miravitlles, C.P. Page, P. Palange, D. Parr, M. Pistolesi, S.I. Rennard, M.P. Rutten-van Molken, R. Stockley, S.D. Sullivan, J.A. Wedzicha, E.F. Wouters, American Thoracic Society, and European Respiratory Society Task Force on Outcomes of COPD Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J. 31 2008 416 469
9. M. Cazzola, and C. Page Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe 10 2014 110 120
10. M. Cazzola, P. Rogliani, and M.G. Matera Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease Expert Opin. Pharmacother. 14 2013 775 781
11. B.R. Celli, and W. MacNee Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur. Respir. J. 23 2004 932 946
12. B.R. Celli, D.P. Tashkin, S.I. Rennard, J. McElhattan, and U.J. Martin Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD Respir. Med. 105 2011 1176 1188
13. J.F. Donohue Minimal clinically important differences in COPD lung function COPD 2 2005 111 124
14. W. Freas, J.L. Hart, D. Golightly, H. McClure, and S.M. Muldoon Contractile properties of isolated vascular smooth muscle after photoradiation Am. J. Physiol. 256 1989 H655 H664
15. A. Gavalda, M. Miralpeix, I. Ramos, R. Otal, C. Carreno, M. Vinals, T. Domenech, C. Carcasona, B. Reyes, D. Vilella, J. Gras, J. Cortijo, E. Morcillo, J. Llenas, H. Ryder, and J. Beleta Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile J. Pharmacol. Exp. Ther. 331 2009 740 751
16. A. Gavalda, I. Ramos, C. Carcasona, E. Calama, R. Otal, J.L. Montero, S. Sentellas, M. Aparici, D. Vilella, J. Alberti, J. Beleta, and M. Miralpeix The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide Pulm. Pharmacol. Ther. 28 2014 114 121
17. GINA, 2011. Global Initiative for Asthma. Guidelines: Global Strategy for Asthma Management And Prevention (GINA). Available from: (accessed 31.01.15).
18. N.J. Gross, and M.S. Skorodin Role of the parasympathetic system in airway obstruction due to emphysema N. Engl. J. Med. 311 1984 421 425
19. E.B. Haddad, H. Patel, J.E. Keeling, M.H. Yacoub, P.J. Barnes, and M.G. Belvisi Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways Br. J. Pharmacol. 127 1999 413 420
20. K. Hatake, and I. Wakabayashi Ethanol suppresses l-arginine-induced relaxation response of rat aorta stimulated with bacterial lipopolysaccharide Nihon Arukoru Yakubutsu Igakkai Zasshi 35 2000 61 68
21. A. Karabis, L. Lindner, M. Mocarski, E. Huisman, and A. Greening Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis Int. J. Chronic Obstr. Pulm. Dis. 8 2013 405 423
22. E. Kerwin, J. Hebert, N. Gallagher, C. Martin, T. Overend, V.K. Alagappan, Y. Lu, and D. Banerji Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur. Respir. J. 40 2012 1106 1114
23. T. Koumis, and S. Samuel Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease Clin. Ther. 27 2005 377 392
24. F.P. Maesen, J.J. Smeets, T.J. Sledsens, F.D. Wald, and P.J. Cornelissen Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group Eur. Respir. J. 8 1995 1506 1513
25. M.G. Matera, C.P. Page, and M. Cazzola Novel bronchodilators for the treatment of chronic obstructive pulmonary disease Trends Pharmacol. Sci. 32 2011 495 506
26. M.G. Matera, P. Rogliani, and M. Cazzola Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease Expert Opin. Pharmacother. 15 2014 961 977
27. J. Milara, E. Gabarda, A. Gavalda, J. Beleta, E. Morcillo, J. Cortijo, and M. Miralpeix Functional profile of aclidinium bromide in isolated human bronchi and left atria Medicine 1 2011 3
28. J. Milara, E. Gabarda, A. Gavaldà, M. Miralpeix, J. Beleta, E. Morcillo, and J. Cortijo An assessment of the functional profile of aclidinium in human bronchi and left atria Eur. Respir. J. 38 2011 859
29. K. Richter, S. Stenglein, M. Mucke, C. Sieder, S. Schmidtmann, U. Harnest, G. Weidinger, and H. Magnussen Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD Respiration 73 2006 414 419
30. P. Rogliani, L. Calzetta, E.A. Rendina, D. Massullo, M. Dauri, B. Rinaldi, A. Capuano, and M.G. Matera The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle Pulm. Pharmacol. Ther. 26 2013 325 331
31. D.A. Sykes, M.R. Dowling, and S.J. Charlton Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor Mol. Pharmacol. 76 2009 543 551
32. D.A. Sykes, M.R. Dowling, J. Leighton-Davies, T.C. Kent, L. Fawcett, E. Renard, A. Trifilieff, and S.J. Charlton The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium J. Pharmacol. Exp. Ther. 343 2012 520 528
33. T. Takahashi, M.G. Belvisi, H. Patel, J.K. Ward, S. Tadjkarimi, M.H. Yacoub, and P.J. Barnes Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways Am. J. Respir. Crit. Care Med. 150 1994 1640 1645
34. D.P. Tashkin, and L.M. Fabbri Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Respir. Res. 11 2010 149
35. J.A. van Noord, T.A. Bantje, M.E. Eland, L. Korducki, P.J.G. Cornelissen, and on behalf of the the Dutch Tiotropium Study Group A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease Thorax 55 2000 289 294
36. J.A. van Noord, J.J. Smeets, F.L. Custers, L. Korducki, and P.J. Cornelissen Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease Eur. Respir. J. 19 2002 639 644
37. J. Vestbo, C. Vogelmeier, J. Creemers, M. Falques, A. Ribera, and E.G. Gil Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD COPD 7 2010 331 336